re: Ann: Axiron Net Sales for the Quarter to ... And back to normal now.
Do the milestone payments add to the PE/r of ACR? I guess they would. Still one of our best biotechs, and passing the regulatory hurdle on safety seems possible. Axiron launched in new and important markets.
If a company was to take this one over, and thought the milestone payments were possible, it could keep the dividends to themselves and profit magnificently.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
-0.001(5.26%) |
Mkt cap ! $7.339M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $11.58K | 619.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 335415 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 516258 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |